Ligand Pharmaceuticals (LGND) Asset Writedowns and Impairment (2010 - 2014)

Ligand Pharmaceuticals has disclosed Asset Writedowns and Impairment across 4 years of filings, most recently posting $3.2 million for Q4 2014.

• Asset Writedowns and Impairment for Q4 2014 came in at $3.2 million, up 2747.37% year-over-year; the trailing twelve-month figure through Mar 2015 was $3.1 million (up 230.21% YoY), and the FY2015 annual result was $1.3 million, down 58.93% from the prior year.
• Asset Writedowns and Impairment came in at $3.2 million for Q4 2014 at Ligand Pharmaceuticals, up from -$109000.0 in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $5.1 million in Q3 2010 to a low of -$643000.0 in Q3 2012.
• The 4-year median for Asset Writedowns and Impairment is $270000.0 (2010), against an average of $906666.7.
• Peak annual rise in Asset Writedowns and Impairment reached 2747.37% in 2014, while the deepest fall reached 121.8% in 2014.
• Ligand Pharmaceuticals' Asset Writedowns and Impairment stood at $313000.0 in 2010, then soared by 212.14% to $977000.0 in 2012, then slumped by 88.33% to $114000.0 in 2013, then surged by 2747.37% to $3.2 million in 2014.
• The last three Asset Writedowns and Impairment figures came in at $3.2 million (Q4 2014), -$109000.0 (Q2 2014), and $109000.0 (Q1 2014), per Business Quant data.